REVEL PHARMACEUTICALS INC.

Address: 2325 3RD ST STE 214 SAN FRANCISCO, CA 94107-3197
County: SAN FRANCISCO
Country: UNITED STATES
UEI: RBFMLGKG8KZ3

Issue Date FY

Legal Entity Zip Code

Issue Date FY: 2025 ( Subtotal = $1,721,470 )

2025

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R44AG084351

Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts

000

NIH

8/14/2025

$1,364,162

2025

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43EY036695

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic retinopathy

000

NIH

7/25/2025

$358,065

2025

2024

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43DK137624

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease

000

NIH

12/4/2024

2025

2024

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43GM154502

An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts

000

NIH

8/18/2025

-$77

2025

2024

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43DK137624

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease

001

NIH

8/27/2025

-$182

2025

2023

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43AA030937

An enzyme-based assay for the detection of acetaldehyde-protein adducts

000

NIH

11/7/2024

-$19

2025

2023

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43AG084351

Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts

000

NIH

11/26/2024

-$479

Issue Date FY: 2024 ( Subtotal = $670,770 )

2024

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43DK137624

Development of advanced glycation end product (AGE)-breaking enzymes as a novel therapy for the treatment of diabetic kidney disease

000

NIH

4/29/2024

$324,015

2024

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43GM154502

An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts

001

NIH

9/24/2024

2024

REVEL PHARMACEUTICALS INC.

2325 3RD ST STE 214

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43GM154502

An enzyme-based assay for the detection of carboxyethyl lysine-protein adducts

000

NIH

7/1/2024

$346,755

Issue Date FY: 2023 ( Subtotal = $549,760 )

2023

REVEL PHARMACEUTICALS INC.

2325 3RD STREET

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43AA030937

An enzyme-based assay for the detection of acetaldehyde-protein adducts

000

NIH

7/20/2023

$272,137

2023

REVEL PHARMACEUTICALS INC.

2325 3RD STREET

SAN FRANCISCO

94107-3197

SAN FRANCISCO

USA

R43AG084351

Development of enzymatic tools for rapid measurement of Advanced Glycation End Product-protein adducts

000

NIH

8/14/2023

$277,623

All Categories

About

Search

Reports

Data Submission

Recipient Information

REVEL PHARMACEUTICALS INC.

Address: 2325 3RD ST STE 214 SAN FRANCISCO, CA 94107-3197

County: SAN FRANCISCO

Country: UNITED STATES

UEI: RBFMLGKG8KZ3

Issue Date FY Summary

Issue Date FY by OPDIV

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer